We are live on ! Find out more
CM

Caption Management Portfolio holdings

AUM $17.1B
1-Year Est. Return 70.99%
This Fund
S&P 500
This Quarter Est. Return
+8.37%
1 Year Est. Return
+70.99%
3 Year Est. Return
+176.06%
5 Year Est. Return
+263.89%
10 Year Est. Return
AUM
$14.6B
AUM Growth
+$1.76B
Cap. Flow
+$1.61B
Cap. Flow %
11.04%
Top 10 Hldgs %
12.14%
Holding
2,182
New
575
Increased
392
Reduced
342
Closed
670

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$126M
2
NVDA icon
NVIDIA
NVDA
+$123M
3
NFLX icon
Netflix
NFLX
+$81.9M
4
MSFT icon
Microsoft
MSFT
+$52.2M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$51M

Sector Composition

Rank Sector Weight
1 Technology 4.6%
2 Consumer Discretionary 2.55%
3 Healthcare 2.5%
4 Communication Services 1.71%
5 Financials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BRSP
1276
BrightSpire Capital
BRSP
$683M
$398K ﹤0.01%
71,152
-12,249
-15% -$67.4K
MEOH icon
1277
Methanex
MEOH
$4.19B
$398K ﹤0.01%
10,018
PTEN icon
1278
PUT
Patterson-UTI
PTEN
$3.57B
$398K ﹤0.01%
65,100
WTI icon
1279
W&T Offshore
WTI
$492M
$395K ﹤0.01%
242,379
+186,986
+338% +$359K
PLUG icon
1280
CALL
Plug Power
PLUG
$2.87B
$394K ﹤0.01%
200,000
HUM icon
1281
Humana
HUM
$45.8B
$394K ﹤0.01%
1,538
-18,462
-92% -$4.84M
CLOV icon
1282
CALL
Clover Health Investments
CLOV
$2.25B
$393K ﹤0.01%
+167,200
New +$457K
BCRX icon
1283
CALL
BioCryst Pharmaceuticals
BCRX
$2.43B
$390K ﹤0.01%
50,000
+1,800
+4% +$13K
BCRX icon
1284
PUT
BioCryst Pharmaceuticals
BCRX
$2.43B
$390K ﹤0.01%
+50,000
New +$361K
BCAX
1285
Bicara Therapeutics
BCAX
$1.83B
$387K ﹤0.01%
+23,000
New +$393K
OPK icon
1286
CALL
Opko Health
OPK
$936M
$387K ﹤0.01%
306,800
CRVS icon
1287
Corvus Pharmaceuticals
CRVS
$1.09B
$380K ﹤0.01%
49,325
+27,498
+126% +$217K
BW icon
1288
CALL
Babcock & Wilcox
BW
$1.4B
$379K ﹤0.01%
+59,800
New +$295K
DAVEW icon
1289
Dave Inc Warrants
DAVEW
$34.3M
$374K ﹤0.01%
381,431
+80,205
+27% +$81.6K
COGT icon
1290
CALL
Cogent Biosciences
COGT
$6.91B
$373K ﹤0.01%
10,500
-369,500
-97% -$10.4M
CZR icon
1291
Caesars Entertainment
CZR
$6.1B
$373K ﹤0.01%
15,936
-71,284
-82% -$1.6M
PAR icon
1292
PAR Technology
PAR
$682M
$363K ﹤0.01%
+10,000
New +$361K
DHC
1293
Diversified Healthcare Trust
DHC
$2.28B
$362K ﹤0.01%
74,663
+27,882
+60% +$126K
TMC icon
1294
CALL
TMC The Metals Company
TMC
$1.64B
$361K ﹤0.01%
58,500
DOCN icon
1295
CALL
DigitalOcean
DOCN
$14.1B
$361K ﹤0.01%
+7,500
New +$330K
BTG icon
1296
B2Gold
BTG
$5.16B
$361K ﹤0.01%
80,000
BZAIW
1297
Blaize Holdings Warrants
BZAIW
$6.89M
$359K ﹤0.01%
898,556
+419,565
+88% +$295K
WRAP icon
1298
CALL
Wrap Technologies
WRAP
$99.8M
$357K ﹤0.01%
+150,000
New +$362K
RLMD icon
1299
CALL
Relmada Therapeutics
RLMD
$546M
$355K ﹤0.01%
+73,600
New +$247K
WOR icon
1300
Worthington Enterprises
WOR
$2.79B
$351K ﹤0.01%
6,800

Similar funds

Caption Management's Q4 2025 Portfolio in Review

As of Q4 2025, Caption Management held 2,182 positions worth $14.6B, up 14% from $12.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Caption Management deployed $1.61B of net new capital in Q4 2025, opening 575 new positions and adding to 392 existing holdings. Its largest new stake was Apple: 470,000 shares worth $128M.

By sector, the portfolio is most concentrated in Technology at 4.6% of assets, up from 2.7% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Tesla, an estimated $22.2M trimmed.

  • Caption Management's largest Q4 2025 buy was Apple: 470,000 shares worth $128M.
  • Caption Management added most to NVIDIA in Q4 2025, an estimated $123M increase.
  • Caption Management's biggest Q4 2025 reduction was Tesla, cutting an estimated $22.2M.
  • Caption Management fully exited EchoStar in Q4 2025, selling an estimated $34.1M.
  • Caption Management's ten largest holdings make up 12% of its $14.6B portfolio in Q4 2025.
  • Caption Management opened 575 new positions and closed 670 in Q4 2025.
  • Caption Management's portfolio value rose 14% quarter-over-quarter to $14.6B.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.